Limited knowledge exists of the extent of epigenetic alterations, such as DNA methylation, in heart failure (HF). We conducted targeted DNA methylation sequencing to identify DNA methylation alterations in coding and noncoding RNA (ncRNA) across different etiological subtypes of HF.
I mportant pathological mechanisms that regulate gene expression involve epigenetic modifications, such as methylation of DNA and noncoding RNA (ncRNA). Several comprehensive reports have suggested their plausible role in heart failure (HF) pathogenesis. 1 Specifically, DNA methylation is a unique epigenetic process for fine-tuning of gene expression in line with the needs of the body and in response to the ever-changing environmental milieu. 2 This process is conserved and commonly linked to transcriptional gene repression as it can prevent binding of transcription factors to the DNA or limit the access to gene regulatory regions.
Aberrant patterns of DNA methylation have been shown to contribute to maladaptive cardiac remodeling, including hypertrophy, fibrosis, ischemia, and inflammation, as well as to occur as a consequence of these disease processes. 3 To date, studies that have assessed DNA methylation profiling in HF patients have mostly used whole-genome bisulfite sequencing to assess global changes in methylation and epigenomic patterns in blood or cardiac tissue from patients from a single HF cause (end-stage ischemic/idiopathic HF, dilated cardiomyopathy [DCM] , ischemic cardiomyopathy [ISCM]) compared with a non-HF control group. However, no study has so far examined DNA methylation signatures in other significant HF causes such as hypertrophic cardiomyopathy (HCM), in particular hypertrophic obstructive cardiomyopathy (HOCM), and no study has used a targeted methylated capture approach to examine DNA methylation in genes associated specifically with the HF syndrome. Such methylation signatures could be used to discover novel diagnostic and therapeutic targets for HF.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request. Custom-designed next generation targeted methylation sequencing was performed in left ventricular (LV) septal tissues of 39 male patients who underwent orthotropic cardiac transplantation for ISCM (9) , DCM (9), or septal myectomy for HOCM (12) , and in matched control patients with nonfailing hearts (9) who died of noncardiac causes. The study conformed to the principles outlined in the Declaration of Helsinki and patients gave informed consent. Ethical approval for data collection and the use of tissue was obtained from the Cleveland Clinic Institutional Review Board. See Material in the Data Supplement for a detailed description of the Methods.
RESULTS

Clinical Classification of the Studied Patient Cohort
Characteristics of the studied patient cohort are listed in Table I in the Data Supplement. There was no statistically significant difference in age and body mass index between the groups.
Altered DNA Methylation in HF Patients
A total of 62 678 500 bp-long differentially methylated regions (DMRs) were analyzed for altered methylation in interventricular septal tissue. A difference in methylation of ≥10% at 5× coverage with a 5% false discovery rate in each HF patient group when compared with the nonfailing control group were considered for further analysis. We identified 195 unique DMRs in the HF cohorts versus control: 5 in HOCM, 151 in DCM, and 55 in ISCM patients.
Non-negative matrix factorization clustering ( Figure  [A] ) demonstrates subtle differences between HF subgroups. Such findings were expected considering that analyzed tissues were sourced from the LV septum and that the studied cohort consisted of HF patients who, despite differences in cause, have common cardiac remodeling features. This is in contrast to other disease types such as cancer where big methylation differences are expected and evident. Negative matrix factorization clustering allowed a distinctive separation of the HOCM cohort, and to some degree in the DCM group, which had the greater number of identified DMRs. This was further supported by the principal component analysis plots ( Figure I in the Data Supplement) which indicated that patient samples from different HF disease groups are not highly divergent in the first 2 principal components but do cluster/separate as expected.
The identified regions were next annotated against known protein-coding genes and ncRNA and subdivided into regions with increased (hypermethylated) and reduced (hypomethylated) methylation (Figure [B] ). In the HOCM patient group, 4 protein-coding genes (3 hypermethylated and 1 hypomethylated) and 1 ncRNA (1 hypomethylated) were found to be differentially methylated. The DCM group was the most divergent with 131 protein-coding genes (13 hypermethylated and 118 hypomethylated) and 17 ncRNA (3 hypermethylated and 14 hypomethylated) identified as having altered methylation profiles. In ISCM patients, 51 protein-coding genes (8 hypermethylated and 43 hypomethylated) and 5 ncRNA (3 hypermethylated and 2 hypomethylated) were differentially methylated. Venn diagrams were created to illustrate protein-coding genes and ncRNA which were methylated in ≥1 patient group(s) (Figure [C] ).
Aberrant DNA Methylation Regulates Protein-Coding Gene and ncRNA Expression in HF Patients
To examine the impact of DNA methylation alterations at specific loci on gene expression, quantitative reverse transcription polymerase chain reaction analysis was performed on a subset of 28 protein-coding genes and 5 micro RNA (miRNA), which exhibited differential DNA promoter methylation in ≥1 of the studied HF groups (Table II in the Data Supplement). Quantitative reverse transcription polymerase chain reaction was performed for all 39 patients. The 28 coding/ncRNA were selected based on several criteria described in Material in the Data Supplement.
The analysis showed significantly altered expression of 6 protein-coding genes and 2 miRNA in ≥1 HF groups (Table) . In silico analysis of the specific methylated regions identified in the putative promoters (−2000/+500 bp from the transcriptional start site) of these coding/ncRNA revealed that these sites contain active transcription marks including H3K27ac (UCSC genome browser, hg19). This supports the fact that the methylation alterations at such potential regulatory regions could plausibly impact gene expression across the various sample types.
Within this context, of the identified 6 protein-coding genes with significantly altered gene expression, 4 were hypermethylated (hairy/enhancer-of-split related with YRPW motif protein 2 (HEY2), macrophage scavenger receptor 1 (MSR1), myomesin 3 (MYOM3), and cytochrome C oxidase copper chaperone (COX17)) and 2 were hypomethylated (connective tissue growth factor (CTGF) and matrix metalloproteinase 2 (MMP2)). Moreover, the patterns of gene expression were consistent with the direction of DNA methylation, that is, genes with hypermethylated promoters incurred reduced gene expression compared with the nonfailing group, whereas those with hypomethylated promoters had increased gene levels.
Among 100% (1, yellow) . B, Bar graphs illustrating the number of hypermethylated and hypomethylated protein-coding genes and noncoding RNA in HOCM, DCM, and ISCM groups as compared to the control, NF group. Differential hypomethylation of promoter regions is prominent in all 3 groups. C, Venn diagrams illustrating differential methylation profiles of HOCM, DCM, and ISCM as compared to NF control, in terms of the number of protein-coding genes (left) and noncoding RNA (micro RNA and long noncoding RNA, right) involved. Methylation events specific to 1 and >1 patient group are shown. HOCM is depicted in purple color; DCM, in green; and ISCM, in blue. NMF indicates negative matrix factorization.
boring DMRs (Table) . Expression levels of MMP2 were increased by 2.67-fold in DCM (P=0.003), and CTGF was upregulated by 2.85-fold in ISCM (P=0.005) and 3.33-fold in DCM (P=0.011).
From a ncRNA perspective, DNA methylation analysis showed the miR-23b/miR-27b/miR-24-1 cluster to be significantly hypermethylated in ISCM (11.27%, P=0.035) and DCM (15.08%, P=0.003) at 2 different regions and miR-155 to be hypomethylated in ISCM (16.41%, P=0.005). While we did not find significant differences in the expression of miR-23b or miR-27b (data not shown), the expression of miR-24-1 was significantly reduced by 0.81-fold in the ISCM group only (P=0.031). MiR-155 expression was increased by 1.63-fold in ISCM patients (P=0.030), tandem with its hypomethylation profile in this group.
DISCUSSION
DNA methylation alterations are dynamic epigenetic modifications, leading to a widespread regulation of gene expression. Despite the vast clinical potential of DNA methylation sequencing not many studies to date have used this technique to identify disease-associated methylation changes in HF patients. In this study for the first time, we performed targeted DNA methylation profiling to identify patterns characteristic for HOCM, DCM, and ISCM causes.
We report 5 novel significantly expressed differentially methylated regions in HOCM, 151 in DCM, and 55 in ISCM patients. The identified novel DMRs were found to associate with the promoter regions of a number of protein-coding genes and ncRNA, some of which have been shown to regulate key processes in HF underlined by HCM, DCM, or ISCM. We also identified 2 novel HOCM-related genes, HEY2 and MSR1, which were deregulated in disease. We identified significant hypermethylation in HEY2 and MSR1 complemented with considerably reduced expression of these genes in HOCM tissue. HEY2 is an important effector in the Notch developmental pathway with a critical role in heart development, and studies have demonstrated HEY2 mutations and deletions in patients with atrioventricular septal defects. 4 Our finding of reduced HEY2 expression likely because of increased methylation in HOCM patients is a novel discovery highlighting DNA methylation as an additional mechanism of HEY2 silencing in HCM. Likewise, we report novel hypermethylation and aberrant expression of MSR1 in HOCM. MSR1 is a macrophage-restricted gene responsible for optimized inflammatory response and lipid homeostasis and its deletion has been reported to cause cardiac rupture following an experimental ischemic insult (myocardial infarction). 5 Thus, our study demonstrates DNA hypermethylation as a likely regulatory mechanism that controls expression of these 2 genes novel to HOCM.
From the methylation analysis in DCM tissue, we report hypomethylation with significantly elevated gene expression of 2 genes important for the turnover and stability of the ECM (extracellular matrix)-MMP2 and CTGF. MMP2 is a well-known regulator of collagen turnover and fibrosis, and we and others have reported higher levels of this protein in peripheral serum and heart tissue of patients at risk for or with established HF including HF because of DCM. 6, 7 Likewise, CTGF is primarily implicated in ECM fibrosis in DCM and is highly *miR-24-1 hypermethylation is identified as part of the miR23b/miR27b/miR-24-1 cluster.
expressed in failing hearts 7 ; moreover, CTGF inhibition has been shown to significantly improve LV function and slow the progression of LV dilatation in a mouse model of DCM. 8 So far, cardiac studies have been limited in providing a mechanistic insight into the regulation of MMP2 and CTGF in HF and our study for the first time reports methylation as a likely mechanism for gene regulation.
Analysis of ISCM tissue revealed hypermethylation and diminished gene expression of MYOM3 and COX17, and hypomethylation of CTGF with elevated gene expression. MYOM3 is one of 3 myomesin genes which have complex roles in muscle contractility and myofibril assembly. COX17 is a copper chaperone for cytochrome c oxidase and a highly conserved protein in the mitochondrial respiratory chain. It is implicated in several processes including heart development and its deficiency is associated with end-stage DCM. 9 With relation to hypomethylated genes, we identified significant hypomethylation of CTGF in ISCM patients at a unique region, different to the DMR identified in the DCM group. Expression levels of CTGF were 3× higher than in the control group. Similar findings of increased CTGF expression in LV tissue of ISCM patients were previously reported, 7,10 and authors gave evidence of correlation of CTGF to genes involved in ECM remodeling 10 and localization of CTGF to regions of fibrosis in the failing heart. 7 In addition, CTGF promoter hypomethylation was reported to augment hepatic fibrosis by promoting phenotypic changes of hepatic stellate cells into myofibroblasts. 11 Alongside published data, our data suggest that the regulation of CTGF by DNA methylation promotes adverse cardiac remodeling in the heart of ISCM patients.
From a ncRNA perspective in ISCM, we identified hypermethylation in 2 regions relating to the miR-23b/ miR-27b/miR-24-1 cluster and confirmed reduced expression specifically of miR-24-1. We also found significant hypomethylation and increased expression of miR-155 in ISCM. Though the significance of the miR-23b/miR-27b/ miR-24-cluster in vascular remodeling (particularly neovascularization, atherosclerosis, and aneurysm) has been discussed, 12 there is no evidence linking it, or linking miR-24-1 to HF or ISCM. Similarly, miR-155 is a well-characterized miRNA within the context of cardiovascular remodeling and disease, 12, 13 however, there have been only few studies investigating its role in HF. One recent study assessed the value of several miRNAs to serve as circulating biomarkers of disease and reported increased miR-155 expression in coronary sinus samples from patients with congestive HF.
14 However, our study is the first to show altered miR-155 expression within human cardiac tissue of patients with HF thus highlighting a potential new implication for this miRNA in HF pathogenesis.
In summary, this study provides a novel insight into the DNA methylation landscape of cardiac tissue from HF patients presenting with varied clinical causes (HOCM, DCM, and ISCM) and supports the role of DNA methylation in regulation of disease-associated genes. This study presents an avenue to carry out an additional analysis into the functional role of the methylation-sensitive genes identified herein to determine their precise mechanistic role in HF. Further investigation of the cell type-specific methylation patterns of these methylated protein-coding genes and ncRNAs will provide valuable information of the cardiac cell types (cardiomyocytes, fibroblasts, inflammatory cells, and endothelial cells) involved in the methylation process, that either drives HF pathogenesis or occurs as a result of it, and one new study offers an insight from cardiomyocytes. 15 This proposed analysis would indeed account for the varied cellular composition that may be seen in some HF pathologies.
ARTICLE INFORMATION
